Good morning, welcome to the 2026 Annual Meeting of Stockholders of Maze Therapeutics . Please note that this event is being held live via webcast, and the webcast will be posted on our website for a period of one month after the meeting. I would now like to turn the meeting over to Jason Coloma, Chief Executive Officer of Maze Therapeutics and Chairperson of the annual meeting.
Thank you. Welcome, everyone. I am Jason Coloma, Chief Executive Officer of Maze Therapeutics. Thank you for joining us for our 2026 Annual Meeting of Stockholders. I will act as the Chairperson of the annual meeting. I will now call the meeting to order. We are excited to host our annual meeting virtually with our stockholders attending via virtual webcast. We believe that a virtual stockholder meeting makes it easier for our stockholders to attend and participate in the annual meeting. I would now like to introduce Courtney Phillips, our General Counsel and Corporate Secretary, who will act as Secretary of the annual meeting and keep the minutes.
Thank you, Jason. I am advised by our Inspector of Elections that over a majority of the voting power of our outstanding shares of common stock and entitled to vote at this meeting is present or represented by proxy here today, and that a quorum is therefore present. Later in this meeting, we will describe the proposals to be voted on today. It is now 9:01 A.M. and the polls are open for voting. Voting is by proxy and electronic ballot. Any stockholder who has not voted or who wishes to change his or her vote may do so by clicking on the Vote button on the webcast portal and following the instructions there. Stockholders who have sent in proxies or previously voted via the internet or by phone and who do not wish to change their vote do not need to take further action.
Their votes will be counted automatically. We expect to close the polls shortly after the presentation of matters to be voted on at the meeting and after the question- and- answer session. We will answer stockholders' questions as appropriate regarding the proposals to be voted on at the meeting after all proposals have been presented. Stockholders are limited to one question each. The time permitted for the question- and- answer session will be limited to 10 minutes. Please keep your questions brief and limited to the specific proposals up for a vote.
We may have to interrupt any question that continues for too long. We will respond to as many questions as possible in the time permitted. Please note that stockholders who want to ask a question may do so by submitting the question in writing where indicated on the webcast portal for this meeting. Only validated stockholders are permitted to submit questions, and you must have your 16-digit control number to do so. This meeting is being recorded. However, no one attending via the webcast is permitted to use any audio recording device.
A replay of the meeting webcast will be available for approximately one month at www.virtualshareholdermeeting.com/maze2026. Dr. Coloma and I are joined on this call today by members of our Board of Directors as well as Misbah Tahir, our Chief Financial Officer. We are also joined by Abdul Kazi of Ernst & Young LLP, our independent registered public accounting firm, Chelsea Anderson of Fenwick & West LLP, our outside legal counsel, and Tracy Oates of Broadridge Financial Solutions, who has executed the oath of Inspector of Elections and will act as the Inspector of Elections for this meeting and tabulate results of the voting.
We will now proceed with the formal business of the annual meeting. Our Board of Directors set April 13th, 2026, as the record date for determining the stockholders entitled to vote at the annual meeting. Broadridge has delivered an affidavit attesting that a notice of internet availability of proxy materials was mailed on or about April 28th, 2026, to all of the company stockholders of record determined as of the close of business on the record date.
The affidavit will be incorporated into the minutes of this meeting. Pursuant to the recent amendments to Delaware General Corporation Law, Section 219, a list of the stockholders entitled to vote at this meeting was provided for inspection upon request during ordinary business hours at the company's headquarters for a 10-day period ending yesterday. The list of stockholders shows that as of the record date, there were 49,758,584 shares of our common stock issued and outstanding and entitled to vote at this meeting, with each share of common stock entitled to one vote.
As previously mentioned, the Inspector of Elections has advised that over a majority of the voting power of our shares of common stock outstanding entitled to vote at this meeting is present or represented by proxy, and that a quorum is therefore present. We are therefore authorized to transact business at this meeting. I will now present the two proposals to be voted upon as described in our proxy statement dated April 28th, 2026.
Proposal one is to elect two Class I Directors, each of whom is currently serving as a Director on our Board of Directors, each to be elected for a three-year term expiring at our 2029 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation, disqualification, retirement, or removal. The Director nominees are Jason Coloma, PhD, and Neil Kumar, PhD. No other Director nominees have been properly submitted for election pursuant to our amended and restated bylaws or the Securities and Exchange Commission rules. No other nominations may be accepted.
The Board of Directors recommends a vote for all the nominees in the election of each of the Class I Director nominees. As secretary of this annual meeting, and on behalf of the Board of Directors, I move for the election of each of the nominated directors in Proposal one, which motion is seconded by proxy. Proposal two is to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31st, 2026. The Board of Directors recommends a vote for the ratification of the appointment of Ernst & Young LLP. As secretary of this annual meeting, and on behalf of the Board of Directors, I move for the approval of Proposal two, which motion is seconded by proxy.
We will now address any questions that stockholders submitted that are relevant to Proposal one and Proposal two. Please note that we will not address any questions that are irrelevant to the matters presented at this meeting. As noted earlier, stockholders are limited to one question each, and the time permitted for each question-and-answer session is limited to 10 minutes. If we do not receive any relevant questions, we will conclude the question-and-answer session sooner.
We do not see any questions and therefore we will now proceed to vote on the previously discussed proposals. As noted earlier, the voting today is by proxy and electronic ballot. Any stockholder who has not voted or wishes to vote his or her shares may do so by clicking the vote button on the webcast portal and following the instructions there. Stockholders who have sent in proxies or previously voted via the internet or by phone and who do not wish to change their vote do not need to take further action.
Their votes will be counted automatically. We will leave the polls open briefly to allow anyone who chooses to vote here to cast ballots. It is now 9:00 A.M. I now declare the polls for the 2026 Annual Meeting of Stockholders of Maze Therapeutics, Inc. closed at 9:00 A.M. on June 8th, 2026. The Inspector of Elections has provided the preliminary voting results. Directors elected pursuant to Proposal one are elected by a plurality of the votes cast by the holders of the shares of our common stock present virtually or represented by proxy at the meeting and entitled to vote on this proposal, which means that the two nominees receiving the highest number of four votes will be elected to the Board of Directors.
Based on the results as tabulated by the Inspector of Elections, Jason Coloma and Neil Kumar are the two nominees on the ballot who received the highest number of four votes cast, and therefore each nominee has been elected to the Board of Directors. The vote required to approve Proposal two is the affirmative vote on the majority of the votes cast affirmatively or negatively with respect thereto by the shares present virtually or represented by proxy at the meeting and entitled to vote on this proposal and will be obtained if the number of votes for this proposal exceeds the number of votes against this proposal.
Based on the results as tabulated by the inspector of elections, the proposal to ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31st, 2026, has been approved by a majority of the votes cast. The annual meeting is now adjourned. Final voting results will be recorded in the minutes of this meeting and also filed with the Securities and Exchange Commission on our current report on Form 8-K within four business days. We thank you for attending our annual meeting and for your continued support of the company.
The 2026 Annual Meeting of Stockholders of Maze Therapeutics Inc. has now come to an end. A replay of the meeting webcast will be available for approximately one month at www.virtualshareholdermeeting.com/maze2026. You will now be disconnected from the meeting.